Author(s):
Tushar R Chandan, Chandrashekhar D. Patil, Vitthal B Kundgir, Kavita Chaudhari, Rushikesh L. Bachhav, Mayur S. Bhamare, Sharwari K. Sonawane, Sunil K. Mahajan
Email(s):
tusharchandan510@gmail.com
DOI:
10.52711/2321-5836.2025.00048 
Address:
Tushar R Chandan1*, Chandrashekhar D. Patil1, Vitthal B Kundgir1, Kavita Chaudhari1, Rushikesh L. Bachhav2, Mayur S. Bhamare2, Sharwari K. Sonawane3, Sunil K. Mahajan4.
1Department of Pharmacology, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
2Department of Quality Assurance, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
3Department of Pharmaceutics, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
4Department of Chemistry, SSS’s Divine College Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India - 423301.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2025
ABSTRACT:
The field of pharmacogenomics, which examines how an individual's genetic makeup influences their response to medications, is at the forefront of a paradigm shift in modern healthcare. As part of the broader movement toward personalized medicine, pharmacogenomics enables the development and implementation of tailored therapeutic strategies aimed at optimizing efficacy and minimizing adverse drug reactions (ADRs). Traditional "one-size-fits-all" drug therapies often fail to account for interindividual variability in drug metabolism, efficacy, and toxicity factors now known to be significantly influenced by genetic differences. This review explores the scientific foundations, clinical applications, and ongoing challenges of pharmacogenomics in contemporary medical practice. We discuss the most significant pharmacogenetic markers, including polymorphisms in cytochrome P450 enzymes (such as CYP2D6, CYP2C19, and CYP2C9), drug transporter genes (e.g., SLCO1B1), and genes involved in drug targets and immune responses (e.g., HLA-B, VKORC1). Applications of pharmacogenomics are particularly advanced in oncology, cardiology, psychiatry, and infectious diseases, where genetic testing informs the use of drugs like warfarin, clopidogrel, trastuzumab, and abacavir. The integration of genetic data into clinical workflows holds the promise of not only enhancing therapeutic outcomes but also reducing healthcare costs associated with ineffective treatment and adverse effects. Despite these benefits, widespread adoption of pharmacogenomics is hindered by several challenges, including limited clinician awareness, high testing costs, insufficient regulatory frameworks, and ethical concerns related to privacy and data security. Emerging technologies such as next-generation sequencing (NGS), electronic health record (EHR) integration, and artificial intelligence (AI)-driven decision support are expected to accelerate clinical implementation. Ultimately, pharmacogenomics represents a cornerstone of precision medicine and a revolutionary step toward more individualized, effective, and safe drug therapy. This review highlights current evidence, future prospects, and the systemic changes needed to fully realize the potential of pharmacogenomics in routine clinical practice.
Cite this article:
Tushar R Chandan, Chandrashekhar D. Patil, Vitthal B Kundgir, Kavita Chaudhari, Rushikesh L. Bachhav, Mayur S. Bhamare, Sharwari K. Sonawane, Sunil K. Mahajan. Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy. Research Journal of Pharmacology and Pharmacodynamics. 2025;17(4):311-8. doi: 10.52711/2321-5836.2025.00048
Cite(Electronic):
Tushar R Chandan, Chandrashekhar D. Patil, Vitthal B Kundgir, Kavita Chaudhari, Rushikesh L. Bachhav, Mayur S. Bhamare, Sharwari K. Sonawane, Sunil K. Mahajan. Pharmacogenomics and Personalized Medicine: A Revolution in Drug Therapy. Research Journal of Pharmacology and Pharmacodynamics. 2025;17(4):311-8. doi: 10.52711/2321-5836.2025.00048 Available on: https://rjppd.org/AbstractView.aspx?PID=2025-17-4-10
8. REFERENCES:
1. Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-omics Applications in the Era of Cancer Personal Genomics. 2019:9-30.
2. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharmsci. 2000 Mar; 2:29-41.
3. Sadee W. Drug therapy and personalized health care: pharmacogenomics in perspective. Pharmaceutical Research. 2008 Dec; 25(12): 2713-9.
4. Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020: 369-94.
5. Kelton T. Pharmacogenomics: The rediscovery of the concept of tailored drug therapy and personalized medicine. Health Law. 2006; 19:1.
6. Lam YF. Principles of pharmacogenomics: pharmacokinetic, pharmacodynamic, and clinical implications. In Pharmacogenomics 2019 Jan 1 (pp. 1-53). Academic Press.
7. Hasanzad M, Sarhangi N, Hashemian L, Sarrami B. Principles of pharmacogenomics and pharmacogenetics. In Precision Medicine in Clinical Practice 2022 Oct 1 (pp. 13-32). Singapore: Springer Nature Singapore.
8. Palumbo S, Mariotti V, Pellegrini S. A narrative review on pharmacogenomics in psychiatry: scientific definitions, principles, and practical resources. Journal of Clinical Psychopharmacology. 2024 Jan 1; 44(1): 49-56.
9. van Schaik RH, Bach-Rojecky L, Primorac D. Principles of Pharmacogenetics. InPharmacogenomics in Clinical Practice 2024 Jan 5 (pp. 1-12). Cham: Springer International Publishing.
10. Dodson CH. Pharmacogenomics: Principles and relevance to oncology nursing. Clinical Journal of Oncology Nursing. 2017 Dec 1; 21(6).
11. Ma JD, Lee KC, Kuo GM. Clinical application of pharmacogenomics. Journal of Pharmacy Practice. 2012 Aug; 25(4): 417-27.
12. Quiñones L, Roco Á, Cayún JP, Escalante P, Miranda C, Varela N, Meneses F, Gallegos B, Zaruma-Torres F, Lares-Asseff I. Clinical applications of pharmacogenomics. Revista médica de Chile. 2017 Apr 1; 145(4): 483-500.
13. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ. Application of pharmacogenomics in clinical pharmacology. Toxicology mechanisms and methods. 2006 Jan 1;16(2-3):89-99.
14. Norton RM. Clinical Pharmacogenomics: applications in pharmaceutical R&D. Drug Discovery Today. 2001 Feb 15; 6(4): 180-5.
15. Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. American Journal of Health-System Pharmacy. 2000 May 1; 57(9): 887-98.
16. Severino G, Chillotti C, Stochino ME, Del Zompo M. Pharmacogenomics: state of the research and perspectives in clinical application. Neurological Sciences. 2003 May; 24: s146-8.
17. Singh DB. The impact of pharmacogenomics in personalized medicine. Current Applications of Pharmaceutical Biotechnology. 2020: 369-94.
18. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. Aaps Pharmsci. 2000 Mar; 2:29-41.
19. Sadee W. Drug therapy and personalized health care: pharmacogenomics in perspective. Pharmaceutical Research. 2008 Dec; 25(12): 2713-9.
20. Harrison J. Impact of the Genomics Revolution on Drug Development and Personalized Medicine in Pharmaceutics.
21. Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-omics Applications in the Era of Cancer Personal Genomics. 2019: 9-30.
22. De Leon J. Pharmacogenomics: the promise of personalized medicine for CNS disorders. Neuropsychopharmacology. 2009 Jan; 34(1): 159-72.
23. Paul-Chima O, Ugo E, Chukwudi A. The Role of Pharmacogenomics in Personalized Medicine: Historical Context, Principles, Applications, and Future Challenges. Practice. 14:16.
24. Vizirianakis IS. Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Current Drug Delivery. 2004 Jan 1; 1(1): 73-80.
25. Morganti S, Tarantino P, Ferraro E, D’Amico P, Duso BA, Curigliano G. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Translational Research and Onco-omics Applications in the Era of Cancer Personal Genomics. 2019: 9-30.
26. Amir-Aslani A, Mangematin V. The future of drug discovery and development: shifting emphasis towards personalized medicine. Technological Forecasting and Social Change. 2010 Feb 1; 77(2): 203-17.